Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

N myc (and STAT) Interactor / NMI Antibody [PCRP-NMI-1C1]

In Stock
HuProt Validated
Catalog Number Formulation Size Price
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol
Flow Cytometry (Flow)
1-2ug/million cells


Nmi (for N-Myc interactor) is an interferon inducible protein that associates with multiple transcription factors, including c-Myc, n-Myc, Max, and c-Fos, which contain bHLH-ZIP, bHLH, or Zip domains. Nmi is ubiquitously expressed at low levels throughout various fetal and adult tissues and at higher levels in myeloid leukemias and cell lines overexpressing c-Myc. In addition to binding Myc proteins, Nmi also associates with the Stat family of transcription factors, where it enhances Stat-dependent transcription. Although Nmi lacks an intrinsic DNA binding or activation domain, Nmi enhances the transcriptional activity of the Stat proteins, in response to cytokine stimulation, by recruiting the Stat1 and Stat5 transcriptional coactivators, CREB-binding protein (CBP) and p300. In vitro studies indicate that Nmi, expressed in conjunction with CBP, enhances the transcriptional responsiveness of Stat5 to IL-2 stimulation five-fold over CBP alone by increasing the affinity of Stat proteins for CBP/p300.

Product Properties & Targets

Antibody Type
Species Reactivity
Isotype / Light Chain
IgG2b /
Cellular Localization
Cytoplasm, Nucleus, Secreted
Gene Name
Positive Control
HeLa or K562 cells.
Recombinant full-length human NMI protein
Alternate Names
N-myc-interactor, N-myc and STAT interactor, N myc (and STAT) interactor; N myc interactor; NMI; NMYC and STAT interactor; NMYC interactor

Database Links

Entrez Gene ID

Additional Information

Chromosome Location
Mol. Weight of Antigen


  • Acts as a signaling pathway regulator involved in innate immune system response (PubMed:9989503, PubMed:26342464, PubMed:29038465, PubMed:29350881). In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis (PubMed:9989503, PubMed:29377960). Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription (PubMed:9989503). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 (PubMed:10779520, PubMed:10950963). In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21 (PubMed:26342464). In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:29350881). Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses (By similarity). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion (PubMed:29038465). Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines (PubMed:29038465).

Key References

  • Bao, J. and Zervos, A.S. 1996. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 12: 2171-2176.
  • Sakamuro, D. and Prendergast, G.C. 1999. Oncogene 18: 2942-2954.

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “N myc (and STAT) Interactor / NMI Antibody”

Your email address will not be published. Required fields are marked *


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.